How will Roche’s Elevidys trial affect Europe approval?

Roche plans another Elevidys trial targeting European approval

Roche says it will launch an additional trial of Elevidys, a gene therapy for Duchenne muscular dystrophy, as part of an effort to secure European approval for the controversial medicine.

The plan matters because Elevidys approval in Europe has been tied to ongoing scrutiny of its evidence. By running another study, Roche is effectively seeking more data that European regulators can use to judge both benefit and risk in a way that matches local regulatory expectations.

What Roche is trying to achieve

Roche’s stated focus is to win European approval, and the new trial is positioned as an “attempt” toward that goal. In practice, that usually means:

• generating additional clinical evidence to clarify effectiveness
• strengthening safety characterization
• improving the robustness of the dataset regulators can compare against alternative standards of care

Why this is “controversial”

The provided summary flags Elevidys as controversial, which signals there has been debate around the evidence base. When gene therapies enter regulatory review, regulators commonly demand clarity on durable outcomes and the balance between therapeutic benefit and potential harms.

What to watch for

Key questions raised by the announcement include what the new trial’s endpoints will be, how it will address uncertainties that previously blocked or complicated approval decisions, and whether it will generate results sufficient for European authorities to act.

No details were given in the summary about trial design, participants, or timing—only that Roche plans another trial as a step toward European approval.